
Ono Pharmaceutical
OPHLY | OTC
$5.15
-$0.01 (-0.19%)
At close: Nov 16, 2026, 3:41 PM ET
$5.20
+$0.05 (+0.97%)
Pre-market:
Nov 16, 2026, 9:35 AM ET
Ono Pharmaceutical Company Profile
Company profile explainedCompany Profile
Ono Pharmaceutical Co., Ltd., along with its subsidiaries, operates globally, engaging in the research, development, procurement, and commercialization of pharmaceutical products and diagnostic reagents. Its current portfolio features a range of established treatments, notably in oncology, with products such as the intravenous infusions OPDIVO and KYPROLIS, alongside MEKTOVI, VELEXBRU, ADLUMIZ (tablets), and BRAFTOVI (capsules) for various malignant tumors. Other specialized oncology support includes EMEND capsules and PROEMEND intravenous injections to manage chemotherapy-induced nausea and vomiting, and DEMSER capsules for symptomatic improvement in pheochromocytoma patients. Beyond cancer, Ono offers therapies for prevalent conditions like type 2 diabetes (GLACTIV and FORXIGA tablets), chronic heart failure (CORALAN), and various inflammatory and neurological disorders. Specific offerings in these areas include ONOACT injections for tachyarrhythmia, OPALMON tablets for peripheral circulatory issues, ORENCIA injections for rheumatoid arthritis, RIVASTACH patches for Alzheimer's disease, and ONGENTYS tablets for Parkinson's disease. The company also addresses needs in renal care with PARSABIV intravenous injections for dialysis patients, urological health with STAYBLA tablets for overactive bladder, and respiratory conditions with ONON capsules and dry syrups for bronchial asthma and allergic rhinitis. Furthermore, its offerings extend to musculoskeletal health with JOYCLU intra-articular injections for improving joint function, and RECALBON tablets for osteoporosis. Ono Pharmaceutical is also deeply invested in future medical advancements, with an extensive pipeline of products under development. This pipeline targets a wide array of diseases, encompassing numerous types of cancer, including esophageal, urothelial carcinoma, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular carcinoma, pancreatic, biliary tract, gastric, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, primary central nervous system lymphoma, and myelodysplastic syndrome, as well as addressing virus positive/negative solid carcinoma. Beyond oncology, their research extends to inflammatory and autoimmune disorders such as polymyositis/dermatomyositis, pemphigus, generalized scleroderma, and enthesopathy. They are also developing treatments for conditions affecting the cardiovascular and nervous systems, including tachyarrhythmia, diabetic polyneuropathy, neurodegenerative diseases, narcolepsy, and thrombosis. Established in 1717, Ono Pharmaceutical Co., Ltd. maintains its headquarters in Osaka, Japan.
Key Executives
| Name | Position |
|---|---|
| Gyo Sagara | Chief Executive Officer & Chairman of the Board |
| Toichi Takino | President, Chief Operating Officer & Representative Director |
| Akira Takada | Corporate Executive Officer & Executive Director of CMC & Production |
| Harumi Nakano | Corporate Officer, EVP of Finance & Accounting Division & VP Finance & Accounting Department |
| Hirokazu Kitada | Corporate Officer, Executive VP of Business Strategy & Senior VP of Primary Care |
| Hiromu Habashita | Corporate Officer, Senior Vice President, Discovery & Research |
| Hiroyuki Takahashi | Director of Oncology Business Division |
| Hitoshi Mito | Corporate Officer, Exe. VP of Digital Tech. and VP of IT Strategy & DX |
| Kunihiko Ito | Corporate Officer & Head of Global Business |
| Masaki Ito | Corporate Executive Officer, Chief Officer of Fin. & Accounting div. |
| Masayuki Tanigawa | Corporate Officer, Executive VP of Business Strategy & VP of License |
| Ryuta Imura | Vice President of Corporate Communications |
| Satoshi Takahagi | Vice President of Sustainability Promotion & Corporate Officer |
| Seishi Katsumata | Corporate Officer and Executive Director of Discovery & Research |
| Shinji Takai | Corporate Officer & Executive Vice President of Medical Affairs |
| Takehiro Yamada | Corporate Officer & VP of Risk and Compliance Management Department |
| Tatsuya Okamoto | Corporate Officer & Executive Director of Clinical Development, Oncology Clinical Development Div. |
| Toshihiro Tsujinaka | Corp Sr Ex Off, Chief CMC & Prod, Dig Tech, Glob Qual, Bus Trans Dept Off, Bus Des/Chief Off and Dir |
Ono Pharmaceutical

| Country | Japan |
| IPO Date | Oct 2, 2012 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 4,206 |
| CEO | Gyo Sagara |
Contact Details
8-2, Kyutaromachi 1-chome Osaka,
OS 541-8564 Japan
Stock Details
| Ticker Symbol | OPHLY |
| Exchange | OTC |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | n/a |
| CUSIP Number | 682736103 |
| ISIN Number | US6827361030 |
| SIC Code | n/a |
Recent News
- 19 days ago / businesswire.comOno Pharma Announces Results From Five Phase 2 Clinical Studies of ONO-1110, an Endocannabinoid Modulator
- 3 months ago / businesswire.comOno Pharma Enters into a Drug Discovery Partnership with Aitia in Neurological Diseases
Add to Watchlist
Select watchlists to add or remove OPHLY